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Background. Dengue virus infection typically causes mild dengue fever, but, in severe cases, life-threatening dengue hemorrhag-
ic fever (DHF) and dengue shock syndrome (DSS) occur. The pathophysiological hallmark of DHF and DSS is plasma leakage that
leads to enhanced vascular permeability, likely due to a cytokine storm.
Methods. Ninety patients with dengue during 2010–2012 in Singapore were prospectively recruited and stratiﬁed according to
their disease phase, primary and secondary infection status, and disease severity, measured by plasma leakage. Clinical parameters
were recorded throughout the disease progression. The levels of various immune mediators were quantiﬁed using comprehensive
multiplex microbead-based immunoassays for 46 immune mediators.
Results. Associations between clinical parameters and immune mediators were analyzed using various statistical methods. Po-
tential immune markers, including interleukin 1 receptor antagonist, interferon γ–inducible protein 10, hepatocyte growth factor,
soluble p75 tumor necrosis factor α receptor, vascular cell adhesion molecule 1, and matrix metalloproteinase 2, were signiﬁcantly
associated with signiﬁcant plasma leakage. Secondary dengue virus infections were also shown to inﬂuence disease outcome in terms
of disease severity.
Conclusions. This study identiﬁed several key markers for exacerbated dengue pathogenesis, notably plasma leakage. This will
allow a better understanding of the molecular mechanisms of DHF and DSS in patients with dengue.
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Dengue is an important human arboviral disease that is caused
by infection with 4 antigenically related strains of dengue virus
(DENV-1–4), which belong to the Flaviviridae family [1]. De-
spite extensive worldwide efforts, it remains a major public
health concern: 55% of the world’s population is estimated to
be at risk for DENV infection, and there are approximately
390 million DENV infections annually, of which 96 million
are symptomatic [2]. Infection by any of the 4 DENV serotypes
can cause a wide spectrum of disease manifestations that ranges
from mild, self-limiting dengue hemorrhagic fever (DHF) to se-
vere, life-threatening dengue shock syndrome (DSS). The major
pathophysiological hallmark that determines disease severity
and differentiates DHF and DSS from dengue fever is the degree
of plasma leakage, characterized by rising hematocrit, hypoal-
buminemia, ascites, or pleural effusion [1, 3]. Plasma leakage
is a consequence of increased vascular permeability, in which
a dysfunction of endothelial cells and abnormal hemostasis oc-
curs during the critical phase of the disease (3–7 days of illness
onset) [1, 4]. In cases where plasma leakage becomes extensive,
patients can develop profound hypovolemic DSS with fatal out-
come [5, 6].
Although the pathogenesis of DHF remains elusive, evidence
from clinical studies has indicated extensive immune activation
with the overproduction of cytokines [5]. A cytokine storm was
associated with enhancement of vascular permeability, leading
to plasma leakage in dengue [7, 8]. Furthermore, DENV infec-
tion in immature dendritic cells and macrovascular endothelial
cells increased endothelial permeability through the overpro-
duction of matrix metalloproteinase 9 (MMP-9) and MMP-2,
respectively [9, 10]. Collectively, these studies highlight the
need to examine the role and regulation of host factors in
dengue-associated vascular pathophysiology. While the under-
lying mechanism of the cytokine storm in DENV infections is
still unknown, various factors and activities, including immune
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complexes, enhancing antibodies, complement, cross-reactive
memory T-cell activation, virus virulence, and host genetic
polymorphisms, have been postulated [11].
In this study, we sought to identify immune mediators of
plasma leakage in 90 patients with dengue prospectively recruit-
ed during 2010–2012 as part of the Prospective Adult Dengue
Study at Tan Tock Seng Hospital, Singapore [12]. Patients were
classiﬁed according to phase of DENV infection, primary versus
secondary infection, and severity of plasma leakage. Compre-
hensive multiplex microbead arrays, clinical parameters, differ-
ential patterns of immune mediators, and MMPs were analyzed
to temporally associate with the severity of plasma leakage and
the important inﬂuence of secondary DENV infections. These
ﬁndings will provide useful predictors of signiﬁcant plasma
leakage and have important implications in the development




Written informed consent was obtained from all participants in
accordance with the principles of the Declaration of Helsinki.
All procedures adopted in this study were approved by the Na-
tional Healthcare Group Domain-Speciﬁc Review Board
(DSRB/E/09/00432).
Patients and Plasma Collection
We investigated 90 patients with dengue who were selected
from a group of 400 patients recruited at the Communicable
Disease Centre, Tan Tock Seng Hospital, between January
2010 and September 2012 [11]. Inclusion criteria included
fever ≤5 days after onset of fever and the availability of paired
sera. Diagnostic testing was performed by the Environmental
Health Institute, a World Health Organization Collaborating
Center for Reference and Research on Arbovirus and Its Asso-
ciated Vectors, in Singapore. Patients received a diagnosis of
DENV infection on the basis of detection of DENVNS1 antigen
and DENV RNA [12]. Crossing-point values were used to de-
rive viral loads from a standard curve generated by 10-fold serial
dilutions of a stock containing 108 plaque-forming units/mL.
Patients with inﬂuenza virus infection conﬁrmed by ﬁndings
of polymerase chain reaction analysis at the Department of Lab-
oratory Medicine, Tan Tock Seng Hospital, were included as
controls. Data on demographic characteristics and comorbidi-
ties were collected on admission. Daily clinical data and ﬁnd-
ings of hematological and biochemical laboratory testing were
collected prospectively from patients until they were discharged
from the hospital or reached the recovery phase of illness. Pa-
tients were classiﬁed according to their phase of disease (febrile,
critical, and convalescent), type of infection (primary and sec-
ondary), and severity of plasma leakage (none, mild, and signif-
icant) [1, 13]. Signiﬁcant plasma leakage was deﬁned by a
hematocrit change of >20% in the full blood count or by clinical
detection of free ﬂuid in lungs or abdomen by the treating phy-
sician. Patients with a low serum total protein level (<63 g/L;
normal range, 64–83 g/L) without apparent ﬂuid accumulation
were classiﬁed as having mild plasma leakage. Patients who did
not fulﬁll these criteria are classiﬁed as having no plasma leak-
age. Plasma specimens from patients with dengue and 4 pa-
tients with inﬂuenza (as controls) were collected, aliquoted,
and stored at −80°C until use.
Cytokine Quantiﬁcation in Plasma, Using a Microbead-Based
Immunoassay
Cytokine levels in human plasma were measured simultane-
ously, using a premixed 36-plex Procarta multiplex microbe-
ad-based immunoassay (Affymetrix). The 36 cytokines and
chemokines assayed included epidermal growth factor (EGF),
granulocyte colony-stimulating factor, hepatocyte growth factor
(HGF), interferon (IFN) α2, IFN-γ, interleukin 1β, interleukin
10 (IL-10), interleukin 13 (IL-13), interleukin 17A (IL-17A),
interleukin 17F (IL-17F), interleukin 1 receptor antagonist
(IL-1RA), serum-soluble interleukin 2 receptor antagonist
(sIL-2RA), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin
7 (IL-7), interleukin 8 (IL-8), interleukin 9 (IL-9), IFN-γ–induc-
ible protein 10 (IP-10), IFN-inducible T-cell α chemoattractant,
monocyte chemoattractant protein 1 (MCP-1), MCP-3, macro-
phage migration inhibitory factor, monokine induced by IFN-γ,
macrophage inﬂammatory protein (MIP) 1α, MIP-1β, plasmin-
ogen activator inhibitor type 1, platelet-derived growth factor
BB (PDGF-BB), regulated on activation, normal T-cell ex-
pressed and secreted (RANTES), stem cell factor, transforming
growth factor β1 (TGF-β1), tumor necrosis factor α (TNF-α),
soluble p75 TNF-α receptor (sTNFRp750, thrombopoietin,
serum-soluble TNF-related apoptosis-inducing ligand
(sTRAIL), vascular cell adhesion molecule 1 (VCAM-1), and
vascular endothelial growth factor α (VEGF-α). Plasma levels
were also screened for 10 human MMPs, which included EMM-
PRIN, MMP-1–3, MMP-7–10, MMP-12, and MMP-13, using a
custom-designed multiplex microbead-based immunoassay
(R&D System). Samples were prepared, reagents used, and im-
munoassays performed according to manufacturers’ instruc-
tions. Data were acquired using Luminex FlexMap 3D
instrument (Millipore) and analyzed using Bio-plex Manager
6.0 software (Bio-Rad), based on standard curves plotted
through a 5-parameter logistic curve setting. Levels of IL-17A,
IL-17F, and MCP-3 were below detection limits and therefore
excluded from further analysis.
Data Analysis
Associations between continuous variables and categorical var-
iables with 2 unique values were tested statistically, using the
Mann–Whitney U test. If the categorical variable had >2 unique
values, Kruskal–Wallis tests were performed, followed by Dunn
post hoc tests, to determine the signiﬁcant comparison pairs.
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Associations between categorical variables were tested using
Fisher exact tests or χ2 tests. P values of <.05 were considered
statistically signiﬁcant. The relationship between clinical param-
eters and cytokines was determined using Spearman rank cor-
relation analysis. Correlations characterized by a Spearman
correlation coefﬁcient (r) of >0.5 were considered strong and
are presented. All data analysis was performed using Prism
6.0 (GraphPad software). Two-way hierarchical clustering was
performed as described elsewhere [14].
RESULTS
Secondary DENV Infection Increased the Risk of Plasma Leakage
The 90 adult patients with laboratory-conﬁrmed DENV infec-
tion during the study period were classiﬁed according to their
severity of plasma leakage; 30 had no plasma leakage, 30 had
mild plasma leakage, and 30 had signiﬁcant plasma leakage
[12]. Four patients with inﬂuenza were analyzed as controls.
The majority of the patients were male (70 of 90 [77.8%])
and Chinese (79 of 90 [87.8%]; Table 1). The median age of
this cohort was 38 years (interquartile range, 30.00–43.25
years), and the age of patients with signiﬁcant plasma leakage
was signiﬁcantly higher than that of patients without plasma
leakage (Table 1 and Supplementary Figure 1A). Patients
with secondary DENV infection had an increased risk of
mild (56.7%) and signiﬁcant (70%) plasma leakage as com-
pared to those without prior infection (Table 1). The odds of
having signiﬁcant plasma leakage, given a secondary infection,
were 3.231 times the odds of having no plasma leakage
(P = .0329, by the χ2 test). The odds of having mild plasma
leakage, given secondary infection, were 1.902 times the
odds of having no plasma leakage. This association with se-
verity of plasma leakage was afﬁrmed, as patients without plas-
ma leakage composed 43.3% of the group with secondary
DENV infection.
All 4 DENV serotypes were detected in the study cohort, with
DENV-2 (in 75.6% of patients) being the dominant serotype,
Table 1. Demographic Characteristics of the Study Cohort
Characteristic Influenza B Virus–Infected Patients (n = 4)
Severity of Plasma Leakage
None (n = 30) Mild (n = 30) Significant (n = 30)
Sex
Male 2 26 (86.6) 20 (66.7) 24 (80)
Female 2 4 (13.4) 10 (33.3) 6 (20)
Ethnicity
Chinese 3 25 (83.3) 29 (96.7) 25 (83.3)
Indian 1 4 (13.4) 0 2 (6.7)
Malay 0 0 1 (3.3) 2 (6.7)
Others 0 1 (3.3) 0 1 (3.3)
Age (years)a 31.50 (28.50–34.50) 33.0 (28.00–39.50) 36.5 (26.75–44.00) 40.50 (36.75–47.75)
DENV infection
Primary . . . 16 (53.4) 11 (36.7) 8 (26.7)
Secondary . . . 13 (43.3) 17 (56.7) 21 (70)
Unknown . . . 1 (3.3) 2 (6.6) 1 (3.3)
DENV serotype
1 . . . 3 (10) 7 (23.3) 4 (13.4)
2 . . . 26 (86.7) 20 (66.7) 22 (73.3)
3 . . . 0 1 (3.3) 2 (6.7)
4 . . . 0 1 (3.3) 2 (6.7)
Unknown . . . 1 (3.3) 1 (3.3) 0
Data are no. or no. (%) of patients, unless otherwise indicated.
Abbreviation: DENV, dengue virus.
a Data are median values (interquartile ranges).
Table 2. Clinical Symptoms Experienced by Study Population
Symptom







Nausea 23 22 22
Vomiting 9 5 9
Diarrhea 17 7 13
Abdominal pain 6 4 11
Rash 11 16 10
Petechiae 4 11 6
Lymphadenopathy 2 0 0
Conjunctivitis 1 1 0
Postural hypotension 0 1 1
Medical history
Bleeding (including petechiae) 12 16 10
Mucosal bleeding 10 10 5
Associations between plasma leakage severity with the clinical symptoms were tested
using the Fisher exact test. None of the tests were statistically significant.
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followed by DENV-1 (in 15.6%), DENV-3 (in 3.3%), and
DENV-4 (in 3.3%; Table 1). The clinical symptoms presented
by the patients are listed in Table 2, with nausea (74.4%)
being the most common clinical symptom. However, no signiﬁ-
cant statistical association between clinical symptoms and se-
verity of plasma leakage was observed (Table 2).
In line with previous reports [2, 15], hematological assess-
ment of this study cohort indicated that patients with mild
and signiﬁcant plasma leakage exhibited hypoproteinemia, hy-
poalbuminemia, and thrombocytopenia (Supplementary
Table 1 and Supplementary Figure 1B–D). Plasma leakage
was associated with a signiﬁcant elevation in the hematocrit
change in patients with signiﬁcant plasma leakage (Supplemen-
tary Figure 1E). No statistically signiﬁcant association was ob-
served between severity of plasma leakage and leukocyte
count, differential leukocyte counts, and mean platelet volume
at the point of admission (Supplementary Table 1 and Supple-
mentary Figure 1F).
Laboratory diagnostic tests conﬁrmed that all patients were
DENV positive, based on the detection of either DENV RNA,
by polymerase chain reaction, or NS1 antigen, by enzyme-
linked immunosorbent assay (ELISA; Supplementary Table 2).
Serologically, 65.5% of the patients were found to be immuno-
globulin M positive, while 53.3% and 30% of patients were
found to be immunoglobulin G (IgG) positive when assayed
using indirect and capture IgG ELISA, respectively (Supple-
mentary Table 2).
Temporal Association of Clinical Parameters With Severity of Plasma
Leakage
The temporal association between severity of plasma leakage
and patients’ hematological and biochemical parameters were
evaluated using data collected prospectively encompassing fe-
brile, critical, and convalescent phases of illness. Consistent
with the characteristics presented by patients with severe
DENV infection [16, 17], patients with signiﬁcant plasma
leakage experienced a signiﬁcantly elevated hematocrit change
(Figure 1A and Supplementary Figure 2), a reduction in protein
and albumin levels, and a reduction in platelet count during the
febrile and critical phases, compared with patients without
Figure 1. Differential patterns of clinical parameters among dengue virus (DENV)–infected patients, by plasma leakage severity (none, mild, and significant; A) and DENV
infection status (primary and secondary; B), at febrile (Feb), critical (Cri), and convalescent (Con) disease phases. Data are for 7–30 individuals per group per time point (A) and
2–21 individuals per group per infection per time point. Data are compared and presented as heat maps of normalized scores. In these presentations, the immune mediator
concentrations were scaled between 0 and 1 for each measured immune mediator, and then the average scaled value was computed for each group. Blue colors represent the
lowest average scaled value, while pink colors represent the highest average scaled value. Mann–Whitney U tests were used to determine whether there were any significant
associations between primary and secondary infection at various disease phases for the group with significant plasma leakage. Significant parameters include total protein
levels, albumin levels, platelet counts, white blood cell (WBC) counts, percentages of neutrophils, and neutrophil counts. Abbreviation: MPV, mean platelet volume.
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plasma leakage (Figure 1A). During the critical phase, the white
blood cell count, particularly the neutrophil count, was signiﬁ-
cantly increased in patients with signiﬁcant plasma leakage
(Figure 1A and Supplementary Figure 2).
To determine whether secondary DENV infection inﬂu-
enced disease severity, hematological and biochemical labora-
tory parameters for patients experiencing primary or
secondary DENV infections at different phases of illness
were evaluated (Figure 1B). Patients with no and those with
mild plasma leakage were included for comparison. Patients
experiencing secondary DENV infections presented with
more-severe clinical features, including signiﬁcantly lower
protein and albumin levels and platelet counts during the crit-
ical and convalescent phases (Figure 1B). Signiﬁcantly higher
white blood cell and neutrophil counts during the febrile and
critical phases were more prominent in patients with second-
ary DENV infections (Figure 1B).
Temporal Association of Cytokines Levels With Secondary DENV
Infections in Patients With Signiﬁcant Plasma Leakage
Among the 46 immune mediators evaluated in plasma speci-
mens, levels of 3 (IL-17A, IL-17F, and MCP-3) were below
the detection limit and were excluded from subsequent analysis.
Patients were grouped as described in the previous section and
their data presented in a heat map format (Figure 2A and B).
Levels of immune mediators, including sIL-2RA, sTNFRp75,
IL-13, IL-4, RANTES, EGF, VEGF-α, and VCAM-1, were ele-
vated in all disease phases and plasma leakage groups, relative
to healthy controls (Figure 2A and Supplementary Figure 3). In-
terestingly, levels of IL-1RA, IP-10, and HGF were signiﬁcantly
elevated only in the signiﬁcant plasma leakage group (Supple-
mentary Figure 3). This upregulation was observed notably in
patients with secondary DENV infections (Figure 2A). Speciﬁ-
cally, levels of IP-10, HGF, and sTNFRp75 in patients with sig-
niﬁcant plasma leakage and secondary DENV infection were
signiﬁcantly elevated at multiple time points, exceeding the
upper reference limit observed in specimens from patients
with acute inﬂuenza virus infection (Figure 2B). Levels of
VCAM-1 in patients with signiﬁcant plasma leakage were ele-
vated at multiple time points, exceeding the upper reference
limit obtained from patients with acute inﬂuenza virus infection
but independent of the type of DENV infection (Figure 2B and
Supplementary Figure 3).
Association of MMP-2 and MMP-9 With Severity of Plasma Leakage
MMPs are extracellular proteases physiologically involved
in embryological remodeling, angiogenesis, ovulation, and
wound healing [18].Owing to their proteolytic capability to de-
grade components of extracellular matrix, they have been impli-
cated in causing vascular leakages induced by DENV infections
[9, 10, 19]. DENV infections induce high levels of MMP-2/
MMP-9 that resulted in downregulation of cell adhesion mole-
cules and redistribution of F-actin ﬁbers and caused increased
vascular permeability [9, 10]. To evaluate the association be-
tween MMPs and the severity of plasma leakage in this cohort,
the levels of 10 MMPs during the acute (febrile) and recovery
(convalescent) phase were determined (Figure 3). Among the
10 MMPs analyzed, levels of 4 (MMP-2 and MMP-8–10)
were signiﬁcantly different between febrile and convalescent
phases (Figure 3A–D), while 2 MMPs (MMP-2 and MMP-10)
were signiﬁcantly associated with severity of plasma leakage
(Figure 3E and F). MMP-9, which was previously demonstrated
to be upregulated by DENV-infected immature dendritic cells
and contributed to the molecular pathogenesis of DSS by en-
hancing endothelial permeability [9], was detected at signiﬁ-
cantly elevated levels in all patients during convalescence
(Figure 3C) but was not associated with the severity of plasma
leakage (data not shown). In contrast, MMP-2, which was up-
regulated by DENV-infected primary human macrovascular
endothelial cells and demonstrated to enhance endothelial per-
meability [20], was the only MMP detected at a signiﬁcantly el-
evated level in patients with signiﬁcant plasma leakage during
convalescence (Figure 3E). Interestingly, MMPs were not asso-
ciated with primary/secondary DENV infection (data not
shown).
Temporal Relationships Between Immune Mediators and Clinical
Parameters
The relationship between the immune mediators and clinical
parameters at different phases of illness was evaluated using
Spearman’s correlation analysis, and statistically signiﬁcant cor-
relations, deﬁned as those with a Spearman r of >0.5 or less than
−0.5, are described in Table 3 and Supplementary Tables 3–4.
In patients with signiﬁcant plasma leakage, increasing changes
in hematocrit from the febrile to the critical phases (Figure 1A)
were associated with decreasing levels of IL-1RA and IP-10
(Table 3). In parallel, decreasing levels of albumin and protein
observed in these patients (Figure 1A) were associated with in-
creasing levels of MMP-10, IL-13, and TGF-β and a decreasing
level of EGF (Tables 3 and Supplementary Table 3). Thrombo-
cytopenia (Figure 1A), commonly observed in these patients,
was associated with increasing levels of MMP-10 and
sTNFRp75 and decreasing levels of EGF during the febrile
phase (Table 3). Thrombocytopenia was associated with de-
creasing levels of RANTES and PDGF-BB and increasing levels
of IL-6, IP-10, and IL-10 during the critical phase (Supplemen-
tary Table 3), coinciding with the nadir platelet count in these
patients (Figure 1A). Increasing leukocyte count, particularly
the neutrophil count, was associated with increasing levels of
MMP-8 and MMP-9 during the febrile phase (Table 3) and in-
creasing HGF and IL-1RA levels during the critical phase (Sup-
plementary Table 3). Increasing MMP-9 levels were
signiﬁcantly associated with increasing neutrophil counts in
all plasma leakage groups during the febrile phase (Table 3)
and with mild and signiﬁcant plasma leakage during the conva-
lescent phase (Supplementary Table 4).
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Figure 2. Differential-regulated immune mediator profiles among dengue virus (DENV)–infected patients. A, Patients were first grouped on the basis of plasma leakage
severity (none, mild, and significant). Patients were further divided on the basis of DENV infection status (primary and secondary) at febrile (Feb), critical (Cri), and convalescent
(Con) disease phases (n = 2–21 individuals per group per infection per time point) during the hospitalization period. B, Plasma samples from influenza B virus–infected patients
(Flu) were collected at acute and convalescent disease phases (n = 3–4 individuals per time point) and are included for comparison. Data are compared and presented as heat
maps of normalized scores. Immune mediator levels of healthy, noninfected adults (NI; n = 15) are included as a reference point. In the heat map presentation, the immune
mediator concentrations were scaled between 0 and 1 for each measured immune mediator, and then the average scaled value was computed for each group. Blue colors
represent the lowest average scaled value, whereas pink colors represent the highest average scaled value. Mann–Whitney U tests were used to determine whether there were
any significant associations between primary and secondary infection at various disease phases for the group with significant plasma leakage. Significant immune mediators
include interleukin 1 receptor antagonist (IL-1RA), hepatocyte growth factor (HGF), interferon γ–inducible protein 10 (IP-10), and soluble p75 tumor necrosis factor α receptor
(sTNFRp75). Abbreviations: EGF, epidermal growth factor; G-CSF, granulocyte colony-stimulating factor; IFN-α2, interferon α2; IFN-γ, interferon γ; IL-1β, interleukin 1β; IL-4,
interleukin 4; IL-6, interleukin 6; IL-7, interleukin 7; IL-8, interleukin 8; IL-9, interleukin 9; IL-10, interleukin 10; IL-13, interleukin 13; MCP-1, monocyte chemoattractant protein 1;
MIF, macrophage migration inhibitory factor; MIG, monokine induced by interferon γ; MIP-1α, macrophage inflammatory protein 1α; MIP-1β, macrophage inflammatory protein
1β; PAI-1, plasminogen activator inhibitor type 1; PDGF-BB, platelet-derived growth factor BB; RANTES, regulated on activation, normal T-cell expressed and secreted; SCF,
stem cell factor; sIL-2RA, soluble interleukin 2 receptor antagonist; sTRAIL, serum-soluble tumor necrosis factor–related apoptosis-inducing ligand; TGF-β, transforming growth
factor β; TNF-α, tumor necrosis factor α; TPO, thrombopoietin; VCAM-1, vascular cell adhesion molecule 1; VEGF-α, vascular endothelial growth factor α.
Immune Markers of Plasma Leakage During Dengue • JID 2017:215 (1 January) • 47
DISCUSSION
Immune mediators can be detrimental or protective to patho-
gens [5]. In this prospective cohort study, immune mediator
proﬁles of patients with dengue were extensively studied longi-
tudinally to better understand dengue pathogenesis.
Plasma leakage is a major clinical feature in patients with
DHF and DSS [1] and is caused by increased capillary
permeability [21]. The risk of DHF development can differ ac-
cording to the sequence of secondary DENV serotype infec-
tions, with patients experiencing secondary DENV-2 infection
5–7 times more likely to develop DHF than those with second-
ary DENV-1 and DENV3 infections [22, 23]. Vascular pertur-
bations were reﬂected in this study, in which patients from the
signiﬁcant plasma leakage group exhibited marked hematocrit
Figure 3. Temporal association of matrix metalloproteinases (MMPs) with severity of plasma leakage. Plasma MMPs levels were determined using a microbead-based
immunoassay. A–D, Significant immune mediators between febrile and convalescent disease phases in patients with no, mild, and significant plasma leakage (n = 17–25
individuals/group/time point) include MMP-2 (A), MMP-8 (B), MMP-9 (C), and MMP-10 (D). Data are presented as means ± standard errors of the mean (SEMs). *P < .05,
**P < .01, and ***P < .001, by the 2-tailed Mann–Whitney U test (10 MMPs were tested against the disease phase in each of the 3 plasma leakage severity groups). E
and F, Comparison among patients with no, mild, and significant plasma leakage at febrile and convalescent disease phases. Data are presented as means ± SEMs.
*P < .05, **P < .01, and ***P < .001, by the Kruskal–Wallis test followed by the Dunn multiple comparisons post hoc test (10 MMPs were tested against the plasma leakage
severity groups for each of the 2 disease phases). The brown dotted line indicates plasma MMPs levels in healthy controls.
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change, thrombocytopenia, hypoproteinemia, and hypoalbumi-
nemia. Supported by histological assessment, the lack of endo-
thelial cell destruction, coupled with the transient nature of
plasma leakage, plasma leakage in dengue is mediated by func-
tional rather than anatomical perturbation of capillary endothe-
lial cells [24, 25]. The altered permeability may be induced by
soluble mediators and cross-reactive T-cell activation that
alter endothelial cell permeability, leading to plasma leakage
[26, 27].
The analysis of multiple immune mediators in serum ob-
tained in this adult dengue cohort study revealed a temporal as-
sociation between cytokines and the severity of plasma leakage.
These immune mediators cover a wide range of functions, in-
cluding antiinﬂammatory (IL-1RA), chemotactic (IP-10),
growth factor (HGF), soluble receptor (sTNFRp75), adhesion
(VCAM-1), and enzymatic (MMP-2) activities. Some are prov-
en prognostic markers for severe DENV infection or reported to
be potent permeability enhancing cytokines: TNF-α, IFN-γ, IL-
6, IL-8, VEGF-α, IL-2 and RANTES [25,28–33].However, apart
from these common cytokines, immune mediators such as IL-
1RA, MCP-1, TGF-β, HGF, IP-10, and sTNFRp75 were also as-
sociated with signiﬁcant plasma leakage in this cohort.
Since the 1960s, secondary DENV infection was suggested to
be a risk factor for severe DENV infection (DHF or DSS) [22,
34]. Earlier studies proposed that antibody-dependent enhance-
ment in secondary DENV infections may lead to DHF or DSS
[35]. Here, IL-1RA, HGF, IP-10, and sTNFRp75 were signiﬁ-
cantly higher in secondary DENV infections. Therefore, IL-
1RA, HGF, IP-10, and sTNFRp75 may be used to determine
the severity of plasma leakage in adult patients with dengue
Table 3. Correlation Analysis of Immune Mediators With Clinical Parameters During the Febrile Phase, by Severity of Plasma Leakage
Clinical Manifestation
None Mild Significant
Immune Mediator Spearman ra Immune Mediator Spearman ra Immune Mediator Spearman ra
Percentage change in hematocrit IL-4 −0.52b EGF 0.62c IL-1RA −0.72c
VCAM-1 −0.50b . . . . . . IP-10 −0.52b
Total protein level . . . . . . . . . . . . MMP-10 −0.69c
. . . . . . . . . . . . EGF 0.52b
Albumin level IL-13 −0.52b MCP-1 −0.64d MMP-10 −0.63d
. . . . . . . . . . . . IL-13 −0.51b
Platelet count MMP-10 −0.52d RANTES 0.64c MMP-10 −0.57d
. . . . . . TPO −0.60b sTNFRp75 −0.55b
. . . . . . MMP-9 0.58d EGF 0.52b
. . . . . . MCP-1 −0.58b . . . . . .
. . . . . . MMP-2 −0.57d . . . . . .
. . . . . . MMP-1 0.51b . . . . . .
White blood cell count . . . . . . MMP-9 0.74c MMP-9 0.65d
. . . . . . IFN-γ −0.72c MMP-8 0.64d
. . . . . . MMP-8 0.64c PDGF-BB 0.57d
. . . . . . IL-10 −0.61d . . . . . .
Mean platelet volume . . . . . . MMP-12 −0.54d . . . . . .
. . . . . . sTNFRp75 0.52b . . . . . .
Neutrophil count MMP-9 0.67c MMP-8 0.75c MMP-9 0.77c
. . . . . . MMP-9 0.74c MMP-8 0.69c
. . . . . . IFN-γ −0.56d . . . . . .
Lymphocyte count MMP-2 0.61d IL-10 −0.69c IL-1RA −0.67d
CXCL11 −0.50b IFN-γ −0.68c IFN-α2 −0.61d
IL-1RA −0.50b VCAM-1 0.60d IL-13 −0.59b
. . . . . . PDGF-BB 0.54d IL-1β −0.56b
. . . . . . MIP-1α −0.50b MCP-1 −0.52b
Monocyte count . . . . . . IFN-γ −0.55d CXCL-11 −0.75c
. . . . . . sTRAIL −0.51b MIP-1α −0.53b
Immune mediators were tested against continuous clinical parameters (Supplementary Table 1), using Spearman rank correlations. Significant results with a correlation coefficient >0.5 are
shown.
Abbreviations: EGF, epidermal growth factor; HGF, hepatocyte growth factor; IFN-α2, interferon α2; IFN-γ, interferon γ; IL-1β, interleukin 1β; IL-1RA, interleukin 1 receptor antagonist; IL-4,
interleukin 4; IL-10, interleukin 10; IL-13, interleukin 13; IP-10, interferon γ–inducible protein 10; MCP-1, monocyte chemoattractant protein 1; MIP-1α, macrophage inflammatory protein 1α;
MMP, matrix metalloproteinase; PDGF-BB, platelet-derived growth factor BB; RANTES, regulated on activation, normal T-cell expressed and secreted; sTNFRp75, soluble p75 tumor necrosis
factor α receptor; sTRAIL, serum-soluble tumor necrosis factor–related apoptosis-inducing ligand; TPO, thrombopoietin; VCAM-1, vascular cell adhesion molecule 1.
a A Spearman r of 1 indicates perfect positive correlation, whereas a Spearman r of −1 indicates a perfect negative correlation.
b P < .05.
c P< .001.
d P < .01.
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but also to differentiate between primary and secondary DENV
infections. As such, IL-1RA, HGF, IP-10, and sTNFRp75 may
be useful markers of adult dengue severity that prompt early
medical attention.
It may be an attractive option to include MMP-2 and MMP-9
as predictive markers for plasma leakage in DENV infections
because their roles in increasing endothelial permeability have
been described [9, 10]. The signiﬁcant upregulation of MMP-2
during the convalescent phase in this study suggested its role in
inducing signiﬁcant plasma leakage in adult patients with
dengue. MMP-9 is a core serum protein responsible for plasma
leakage and works with MMP-8 and MMP-10 to exert its func-
tions in dengue pathogenesis. Thus, it is plausible that MMP-9
may induce mild-to-signiﬁcant plasma leakage and exacerbate
disease severity. In contrast, a recent study reported downregu-
lation of MMP-8 and MMP-10 in asymptomatic patients with
dengue [36]. Although this raises the complexity of the MMP
network in driving various disease outcomes in DENV infec-
tions, our study suggests that the severity of plasma leakage is
regulated by different levels of multiple MMPs (including
MMP-2 and MMP-8–10) between healthy and DENV infection
status. Moreover, MMP-2 and MMP-9 were demonstrated to
work in concert with or antagonistic to each other [37–40]. It
would be an interesting idea to consider administering an
MMP-2 and MMP-9 inhibitor (CAS 193807-58-8) to control
severe DENV infection.
Owing to the cocirculation of multiple viruses such as inﬂu-
enza virus and other closely related arboviruses within the same
geographic locations [41, 42], speciﬁc biomarker proﬁles may be
necessary for disease prognosis. HGF and sTNFRp75 levels
were shown to remain low during acute inﬂuenza virus infec-
tion in this study (Figure 2B). Furthermore, although similar
markers such as IFN-γ, IL-6, IL-10, MIP-1β, and MCP-1 can
be found for acute chikungunya virus infection [43], HGF is
unique. Therefore, HGF and perhaps sTNFRp75 may be useful
markers to distinguish the 3 different viral infections often co-
existing in tropical countries. Currently, although no meta-
analysis has summarized the immune mediator proﬁles of dif-
ferent dengue cohorts, the current study provided a set of im-
mune mediators from adult patients with dengue that may be
used to predict dengue disease progression and differentiate
dengue from other ﬂaviviral diseases, such as Zika fever,
which has similar clinical symptoms during early onset of
illness.
Supplementary Data
Supplementary materials are available at http://jid.oxfordjournals.org.
Consisting of data provided by the author to beneﬁt the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
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Supplementary Data 
Supplementary Table 1. Blood and white blood cells profile of study cohort. 
Hematology analysis*  
  Severity of plasma leakage 
Normal level (range) No (n = 30) Mild (n = 30) Significant (n = 30) 
Hematocrit (%) 36-50 
Minimum 41.25 (40.03 - 44.38) 39 (35.40 - 41.50) 36.7 (34.93 - 39.83) 
Maximum   46.45 (44.18 - 48.63) 43.70 (39.70 - 46.83) 46.8 (44.60 - 48.90) 
Hematocrit change over 
minimum (%) 7.98 (6.79 - 12.41) 8.94 (5.83 - 12.77) 21.97 (14.12 - 29.20) 
Minimum protein (g/dL) 63-81 66 (64 - 68) 60 (57 - 61) 58 (52 - 62.25) 
Minimum albumin (g/L) 35-50 38.0 (36.75 - 40.00) 33.0 (30.75 - 36.00) 31.5 (29.75 - 34.25) 
Minimum platelets (106/mL) 150-400 76 (54.25 - 101.50) 41.50 (24.00 - 75.25) 38 (13.00 - 54.00) 
White blood cell (x109/L)a 4-11 2.6 (2.08 - 3.05) 2.15 (1.68 - 2.93) 2.6 (1.78 - 3.30) 
Neutrophils (%) 40-75 57.65 (48.08 - 69.23) 58 (50.43 - 68.85) 64.35 (48.98 - 72.9) 
Lymphocytes (%) 20-45 26.5 (18.83 - 36.95) 28.1 (19.43 - 32. 83) 25.3 (15.28 - 36.43) 
Monocytes (%) 2-10 14.3 (11.53 - 18.08) 13.7 (9.88 - 16.48) 12.65 (9.15 - 16.93) 
Mean platelet volume (fL)a 7.5 - 11.5 8.8 (8.28 - 9.40) 9.0 (8.50 - 9.83) 9.3 (8.48 - 9.65) 
*Data are presented as median (interquartile range) 
aAs determined on the day of admission 
Supplementary Table 2. Laboratory diagnostic assay results in study cohort. 
Laboratory diagnostic assay 
Severity of plasma leakage 
No (n = 30) Mild (n = 30) Significant (n = 30) 
DENV NS1 Antigen detection 27 28 30 
DENV RNA detection 23 24 26 
DENV IgM detection 19 20 20 
Serology IgG (indirect) 5 21 22 
Serology IgG (capture) 15 3 9 
 
Supplementary Table 3. Correlation analysis of immune mediators with clinical parameters during critical phase. Immune 
mediators were tested against the continuous clinical parameters (Supplementary Table 1) using Spearman rank 
correlations. Significant results with a correlation coefficient greater than 0.5 are shown. 
No-Leakage (Critical) Mild-Leakage (Critical) Significant-Leakage (Critical) 
Clinical manifestation Spearman's ra Clinical manifestation Spearman's r Clinical manifestation Spearman's r 
Total Protein: Total Protein: Total Protein: 
  MIP-1α -0.51 (*) TGFβ -0.56 (**) 
    
Albumin: Albumin: Albumin: 
  MIP-1β -0.51 (**) HGF -0.60 (***) TGFβ -0.60 (**) 
  MIP-1α -0.55 (*)   
    
Platelet Count: Platelet Count: Platelet Count: 
  TGFβ -0.53 (**) RANTES 0.64 (***) 
  HGF -0.50 (*) PDGF-BB 0.59 (***) 
  IL-6 -0.55 (**) 
  IP-10 -0.55 (**) 
  IL-10 -0.52 (**) 
    
MPV: MPV: MPV: 
  sTRAIL -0.52 (**) IL-1Ra -0.52 (**)   
  IL-10 -0.50 (*)   
    
Neutrophil Count: Neutrophil Count: Neutrophil Count: 
  HGF 0.68 (***) 
  IL-1Ra 0.51 (**) 
    
Lymphocyte Count: Lymphocyte Count: Lymphocyte Count: 
  MIF -0.54 (**) MIG 0.60 (***) 
  VCAM-1 -0.50 (**) PDGF-BB 0.50 (**) 
                  
aSpearman's r of 1 indicates perfect positive correlation; r of -1 indicates perfect negative correlation.  *p< 0.05; **p< 0.01; ***p< 0.001. 
Supplementary Table 4. Correlation analysis of immune mediators with clinical parameters during convalescent phase. 
Immune mediators were tested against the continuous clinical parameters (Supplementary Table 1) using Spearman rank 
correlations. Significant results with a correlation coefficient greater than 0.5 are shown. 
No-Leakage (Convalescent) Mild-Leakage (Convalescent) Significant-Leakage (Convalescent) 
Clinical manifestation Spearman's ra Clinical manifestation Spearman's r Clinical manifestation Spearman's r 
% Hematocrit change: % Hematocrit change: % Hematocrit change: 
  IL-8 -0.72 (***) MMP-12 -0.50 (*) IL-4 -0.63 (**) 
  IL-4 0.64 (**) IL-13  0.50 (*) 
  IL-1β  0.50 (*) 
    
Total Protein: Total Protein: Total Protein: 
  EMMPRIN 0.60 (*) IL-1β -0.53 (*) MMP-10 -0.66 (**) 
  MMP-3 0.60 (*) MMP-3 -0.62 (**) 
  MMP-1 -0.58 (*)   
  MMP-10 0.51 (*)   
    
Albumin: Albumin: Albumin: 
  MMP-3 0.58 (*)   
  EMMPRIN 0.56 (*)   
    
Platelet Count: Platelet Count: Platelet Count: 
  IL-7 0.56 (**) RANTES 0.53 (**)   
  PAI 0.56 (**) VEGF-α 0.51 (**)   
  IP-10 0.52 (*)   
  VEGF-α 0.51 (**)   
    
WBC Count: WBC Count: WBC Count: 
  MMP-9 0.57 (*) HGF 0.72 (***) 
  MMP-13 -0.50 (*) 
  sTRAIL -0.50 (**) 
    
MPV: MPV: MPV: 
  TPO -0.58 (**) TGFβ 0.53 (**) MIG -0.57 (**) 
  IL-1Ra -0.55 (**) EMMPRIN -0.50 (*)   
    
Neutrophil Count: Neutrophil Count: Neutrophil Count: 
  MMP-9 0.69 (**) HGF 0.68 (***) 
  MMP-8 0.55 (*) VEGF-α 0.54 (**) 
Supplementary Table 4. (continued)
No-Leakage (Convalescent) Mild-Leakage (Convalescent) Significant-Leakage (Convalescent) 
Clinical manifestation Spearman's ra Clinical manifestation Spearman's r Clinical manifestation Spearman's r 
     MMP-9      0.50 (*) 
Lymphocyte Count: Lymphocyte Count: Lymphocyte Count: 
     MMP-2      0.65 (**)      HGF      0.61 (***) 
     IFNγ      -0.62 (***) 
Monocyte Count: Monocyte Count: Monocyte Count: 
     MMP-10      0.61 (**)       IL-6       0.50 (**)      HGF      0.62 (***) 
     MMP-12      -0.50 (*) 
 
aSpearman's r of 1 indicates perfect positive correlation; r of -1 indicates perfect negative correlation.  *p< 0.05; **p< 0.01; ***p< 0.001. 
 Supplementary legends 
Supplementary Figure 1. Association of clinical parameters with severity of plasma leakage. A Kruskal-Wallis test 
followed by Dunn’s post-hoc tests using the clinical parameter age in Table 1 against plasma leakage severity showed 
significant differences in age between the “No” and “Significant” plasma leakage groups (A). Kruskal-Wallis tests followed 
by Dunn’s post-hoc tests were done for the 9 continuous parameters in Supplementary Table 1. Significance was 
observed for (B) minimum protein levels, (C) minimum protein levels, (D) minimum platelet count, (E) % hematocrit 
change, and (F) mean platelet volume. Data are presented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Supplementary Figure 2. Temporal association of clinical parameters with severity of plasma leakage. Significant clinical 
parameters (Supplementary Table 1) among patients from "No", "Mild" and "Significant" plasma leakage groups at febrile, 
critical and convalescent disease phases (n = 7-30 individuals/group/time point) include (A) % hematocrit change, (B) total 
protein levels, (C) albumin levels,  (D) platelet count, (E) WBC count, (F) neutrophil count, and (G) monocyte count. Data 
are presented as mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001, Kruskal-Wallis test. 
Supplementary Figure 3. Differential-regulated immune mediators profiles from dengue-infected patients. Plasma 
cytokine levels were determined using microbead-based immunoassay. Patients were grouped into "No", "Mild" and 
"Significant" plasma leakage groups at febrile, critical and convalescent disease phases (n = 7-30 individuals/group/time 
point). Data are compared and presented in heat map of normalized scores. Immune mediators levels of healthy adults 
(NI, n = 15) were included as reference point. In the heat map presentation, the immune mediator concentrations were 
scaled between 0 and 1 for each measured immune mediator and then the average scaled value computed for each 
group. Blue colors represent the lowest average scaled value while pink colors represent the highest average scaled 
value. Kruskal-Wallis tests followed by Dunn’s post-hoc tests were done at each disease phase comparing the immune 
mediator levels with the plasma leakage groups. Significant elevation of immune mediator levels in “Significant” plasma 
leakage group include IL-1Ra, HGF, IP-10, sTNFRp75 and VCAM-1. 
 
 
 
